Cargando…

Silencing the CSF-1 Axis Using Nanoparticle Encapsulated siRNA Mitigates Viral and Autoimmune Myocarditis

Myocarditis is an inflammatory disease of the heart muscle most commonly caused by viral infection and often maintained by autoimmunity. Virus-induced tissue damage triggers chemokine production and, subsequently, immune cell infiltration with pro-inflammatory and pro-fibrotic cytokine production fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Meyer, Ingmar Sören, Goetzke, Carl Christoph, Kespohl, Meike, Sauter, Martina, Heuser, Arnd, Eckstein, Volker, Vornlocher, Hans-Peter, Anderson, Daniel G., Haas, Jan, Meder, Benjamin, Katus, Hugo Albert, Klingel, Karin, Beling, Antje, Leuschner, Florian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6186826/
https://www.ncbi.nlm.nih.gov/pubmed/30349538
http://dx.doi.org/10.3389/fimmu.2018.02303
_version_ 1783362913690451968
author Meyer, Ingmar Sören
Goetzke, Carl Christoph
Kespohl, Meike
Sauter, Martina
Heuser, Arnd
Eckstein, Volker
Vornlocher, Hans-Peter
Anderson, Daniel G.
Haas, Jan
Meder, Benjamin
Katus, Hugo Albert
Klingel, Karin
Beling, Antje
Leuschner, Florian
author_facet Meyer, Ingmar Sören
Goetzke, Carl Christoph
Kespohl, Meike
Sauter, Martina
Heuser, Arnd
Eckstein, Volker
Vornlocher, Hans-Peter
Anderson, Daniel G.
Haas, Jan
Meder, Benjamin
Katus, Hugo Albert
Klingel, Karin
Beling, Antje
Leuschner, Florian
author_sort Meyer, Ingmar Sören
collection PubMed
description Myocarditis is an inflammatory disease of the heart muscle most commonly caused by viral infection and often maintained by autoimmunity. Virus-induced tissue damage triggers chemokine production and, subsequently, immune cell infiltration with pro-inflammatory and pro-fibrotic cytokine production follows. In patients, the overall inflammatory burden determines the disease outcome. Following the aim to define specific molecules that drive both immunopathology and/or autoimmunity in inflammatory heart disease, here we report on increased expression of colony stimulating factor 1 (CSF-1) in patients with myocarditis. CSF-1 controls monocytes originating from hematopoietic stem cells and subsequent progenitor stages. Both, monocytes and macrophages are centrally involved in mediating tissue damage and fibrotic scarring in the heart. CSF-1 influences monocytes via engagement of CSF-1 receptor, and it is also produced by cells of the mononuclear phagocyte system themselves. Based on this, we sought to modulate the virus-triggered inflammatory response in an experimental model of Coxsackievirus B3-induced myocarditis by silencing the CSF-1 axis in myeloid cells using nanoparticle-encapsulated siRNA. siCSF-1 inverted virus-mediated immunopathology as reflected by lower troponin T levels, a reduction of accumulating myeloid cells in heart tissue and improved cardiac function. Importantly, pathogen control was maintained and the virus was efficiently cleared from heart tissue. Since viral heart disease triggers heart-directed autoimmunity, in a second approach we investigated the influence of CSF-1 upon manifestation of heart tissue inflammation during experimental autoimmune myocarditis (EAM). EAM was induced in Balb/c mice by immunization with a myocarditogenic myosin-heavy chain-derived peptide dissolved in complete Freund's adjuvant. siCSF-1 treatment initiated upon established disease inhibited monocyte infiltration into heart tissue and this suppressed cardiac injury as reflected by diminished cardiac fibrosis and improved cardiac function at later states. Mechanistically, we found that suppression of CSF-1 production arrested both differentiation and maturation of monocytes and their precursors in the bone marrow. In conclusion, during viral and autoimmune myocarditis silencing of the myeloid CSF-1 axis by nanoparticle-encapsulated siRNA is beneficial for preventing inflammatory tissue damage in the heart and preserving cardiac function without compromising innate immunity's critical defense mechanisms.
format Online
Article
Text
id pubmed-6186826
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-61868262018-10-22 Silencing the CSF-1 Axis Using Nanoparticle Encapsulated siRNA Mitigates Viral and Autoimmune Myocarditis Meyer, Ingmar Sören Goetzke, Carl Christoph Kespohl, Meike Sauter, Martina Heuser, Arnd Eckstein, Volker Vornlocher, Hans-Peter Anderson, Daniel G. Haas, Jan Meder, Benjamin Katus, Hugo Albert Klingel, Karin Beling, Antje Leuschner, Florian Front Immunol Immunology Myocarditis is an inflammatory disease of the heart muscle most commonly caused by viral infection and often maintained by autoimmunity. Virus-induced tissue damage triggers chemokine production and, subsequently, immune cell infiltration with pro-inflammatory and pro-fibrotic cytokine production follows. In patients, the overall inflammatory burden determines the disease outcome. Following the aim to define specific molecules that drive both immunopathology and/or autoimmunity in inflammatory heart disease, here we report on increased expression of colony stimulating factor 1 (CSF-1) in patients with myocarditis. CSF-1 controls monocytes originating from hematopoietic stem cells and subsequent progenitor stages. Both, monocytes and macrophages are centrally involved in mediating tissue damage and fibrotic scarring in the heart. CSF-1 influences monocytes via engagement of CSF-1 receptor, and it is also produced by cells of the mononuclear phagocyte system themselves. Based on this, we sought to modulate the virus-triggered inflammatory response in an experimental model of Coxsackievirus B3-induced myocarditis by silencing the CSF-1 axis in myeloid cells using nanoparticle-encapsulated siRNA. siCSF-1 inverted virus-mediated immunopathology as reflected by lower troponin T levels, a reduction of accumulating myeloid cells in heart tissue and improved cardiac function. Importantly, pathogen control was maintained and the virus was efficiently cleared from heart tissue. Since viral heart disease triggers heart-directed autoimmunity, in a second approach we investigated the influence of CSF-1 upon manifestation of heart tissue inflammation during experimental autoimmune myocarditis (EAM). EAM was induced in Balb/c mice by immunization with a myocarditogenic myosin-heavy chain-derived peptide dissolved in complete Freund's adjuvant. siCSF-1 treatment initiated upon established disease inhibited monocyte infiltration into heart tissue and this suppressed cardiac injury as reflected by diminished cardiac fibrosis and improved cardiac function at later states. Mechanistically, we found that suppression of CSF-1 production arrested both differentiation and maturation of monocytes and their precursors in the bone marrow. In conclusion, during viral and autoimmune myocarditis silencing of the myeloid CSF-1 axis by nanoparticle-encapsulated siRNA is beneficial for preventing inflammatory tissue damage in the heart and preserving cardiac function without compromising innate immunity's critical defense mechanisms. Frontiers Media S.A. 2018-10-08 /pmc/articles/PMC6186826/ /pubmed/30349538 http://dx.doi.org/10.3389/fimmu.2018.02303 Text en Copyright © 2018 Meyer, Goetzke, Kespohl, Sauter, Heuser, Eckstein, Vornlocher, Anderson, Haas, Meder, Katus, Klingel, Beling and Leuschner. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Meyer, Ingmar Sören
Goetzke, Carl Christoph
Kespohl, Meike
Sauter, Martina
Heuser, Arnd
Eckstein, Volker
Vornlocher, Hans-Peter
Anderson, Daniel G.
Haas, Jan
Meder, Benjamin
Katus, Hugo Albert
Klingel, Karin
Beling, Antje
Leuschner, Florian
Silencing the CSF-1 Axis Using Nanoparticle Encapsulated siRNA Mitigates Viral and Autoimmune Myocarditis
title Silencing the CSF-1 Axis Using Nanoparticle Encapsulated siRNA Mitigates Viral and Autoimmune Myocarditis
title_full Silencing the CSF-1 Axis Using Nanoparticle Encapsulated siRNA Mitigates Viral and Autoimmune Myocarditis
title_fullStr Silencing the CSF-1 Axis Using Nanoparticle Encapsulated siRNA Mitigates Viral and Autoimmune Myocarditis
title_full_unstemmed Silencing the CSF-1 Axis Using Nanoparticle Encapsulated siRNA Mitigates Viral and Autoimmune Myocarditis
title_short Silencing the CSF-1 Axis Using Nanoparticle Encapsulated siRNA Mitigates Viral and Autoimmune Myocarditis
title_sort silencing the csf-1 axis using nanoparticle encapsulated sirna mitigates viral and autoimmune myocarditis
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6186826/
https://www.ncbi.nlm.nih.gov/pubmed/30349538
http://dx.doi.org/10.3389/fimmu.2018.02303
work_keys_str_mv AT meyeringmarsoren silencingthecsf1axisusingnanoparticleencapsulatedsirnamitigatesviralandautoimmunemyocarditis
AT goetzkecarlchristoph silencingthecsf1axisusingnanoparticleencapsulatedsirnamitigatesviralandautoimmunemyocarditis
AT kespohlmeike silencingthecsf1axisusingnanoparticleencapsulatedsirnamitigatesviralandautoimmunemyocarditis
AT sautermartina silencingthecsf1axisusingnanoparticleencapsulatedsirnamitigatesviralandautoimmunemyocarditis
AT heuserarnd silencingthecsf1axisusingnanoparticleencapsulatedsirnamitigatesviralandautoimmunemyocarditis
AT ecksteinvolker silencingthecsf1axisusingnanoparticleencapsulatedsirnamitigatesviralandautoimmunemyocarditis
AT vornlocherhanspeter silencingthecsf1axisusingnanoparticleencapsulatedsirnamitigatesviralandautoimmunemyocarditis
AT andersondanielg silencingthecsf1axisusingnanoparticleencapsulatedsirnamitigatesviralandautoimmunemyocarditis
AT haasjan silencingthecsf1axisusingnanoparticleencapsulatedsirnamitigatesviralandautoimmunemyocarditis
AT mederbenjamin silencingthecsf1axisusingnanoparticleencapsulatedsirnamitigatesviralandautoimmunemyocarditis
AT katushugoalbert silencingthecsf1axisusingnanoparticleencapsulatedsirnamitigatesviralandautoimmunemyocarditis
AT klingelkarin silencingthecsf1axisusingnanoparticleencapsulatedsirnamitigatesviralandautoimmunemyocarditis
AT belingantje silencingthecsf1axisusingnanoparticleencapsulatedsirnamitigatesviralandautoimmunemyocarditis
AT leuschnerflorian silencingthecsf1axisusingnanoparticleencapsulatedsirnamitigatesviralandautoimmunemyocarditis